Purpose

Phase 2 multicenter study to be conducted in up to 50 qualified participating sites in the United States to assess the efficacy and safety of Reltecimod vs placebo in patients with abdominal sepsis-associated Stage 2/3 AKI.

Conditions

Eligibility

Eligible Ages
Between 18 Years and 80 Years
Eligible Genders
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  1. Has either suspected or documented diagnosis of abdominal sepsis requiring treatment with parenteral antibiotics and planned or completed surgical (laparotomy or laparoscopy) or interventional radiologic procedures within 24 hours of evaluation by medical personnel. Recommended surgical or interventional radiologic procedures be performed with 12 hours of evaluation by medical personnel.
  2. Initial diagnosis of AKI Stage 2 or 3 according to KDIGO AKI criteria established either upon presentation to medical care in those patients with suspected abdominal sepsis or in those patients in whom the initial diagnosis of AKI is established during the 48 hour period from the suspected diagnosis of abdominal sepsis.
  3. Study medication must be administered within 6 hours of confirmation of onset of Stage 2 or 3 AKI as established at the study site, under the following criteria:
  4. After the decision is made by the attending surgeon at the study site for a surgical or interventional radiology procedure for the abdominal infection OR
  5. After confirmed diagnosis of abdominal infection has been established by a surgical or interventional radiology procedure

Exclusion Criteria

  1. Has known prior history of CKD with a documented estimated GFR (eGFR) < 30 mL/min

• Exception: Patients with history of CKD but no available prior eGFR who have documented normal kidney size on ultrasound or computed tomography evaluation (performed within 90 days of screening) will be eligible

2. Patients receiving RRT for chronic kidney disease

3. . Previously diagnosed with documented AKI in the last 30 days

4. Documented primary glomerular disease or toxic tubulo-interstitial nephritis at the time of AKI diagnosis

5. Patient is not expected to survive throughout 28 days of study due to significant underlying medical condition

6. Any concurrent medical condition, which in the opinion of the Investigator, may compromise the safety of the patient or the objectives of the study or the patient will not benefit from treatment such as:

- Congestive heart failure (CHF) {New York Heart Association (NYHA) class III-IV}

- Severe chronic obstructive pulmonary disease (COPD) {GOLD stage IV. or chronic hypoxemia

- Liver dysfunction {Childs-Pugh class C}

- Primary or acquired immunodeficiency or immunosuppression due to treatment with immunosuppressive medications

- Known HIV infection with CD4 count < 200 cells/mm3 or < 14% of all lymphocytes

- Neutropenia < 1,000 cells/mm3 not due to the underlying infection

- Receiving or about to receive chemotherapy or biologic anti-cancer treatment,

- Hematological and lymphatic malignancies in the last 5 years

7. Patient has acute pancreatitis with no established source of infection, uncomplicated appendicitis, or cholangitis or cholecystitis without peritonitis;

8. Pregnant or lactating women

9. Concurrent or previous enrollment in a clinical trial involving investigational drug or a medical device

Study Design

Phase
Phase 2
Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel Assignment
Intervention Model Description
1:1 randomization of study drug (Reltecimod) and placebo (normal saline)
Primary Purpose
Treatment
Masking
Triple (Participant, Care Provider, Investigator)
Masking Description
Sponsor personnel and CRAs will also be blinded to study treatment.

Arm Groups

ArmDescriptionAssigned Intervention
Experimental
Reltecimod
Single dose
  • Drug: Reltecimod
    Single IV administration of 0.5 mg/kg Reltecimod (at a concentration of 1 mg/mL)
    Other names:
    • AB103
Placebo Comparator
0.9% Sodium Chloride Injection
Single dose
  • Drug: 0.9% Sodium Chloride Injection
    Single IV administration of 0.5 mL/kg of 0.9% saline (volume equivalent with Reltecimod dosing schema)
    Other names:
    • Normal saline

Recruiting Locations

Maricopa Medical Center
Phoenix, Arizona 85008

Banner University Medical Center
Tucson, Arizona 24857

University of Arkansas for Medical Sciences
Little Rock, Arkansas 72205

Loma Linda University Medical Center
Loma Linda, California 92354

University of California, Davis Medical Center
Sacramento, California 95817

UCSD Medical Center
San Diego, California 92103

Harbor-UCLA Medical Center
Torrance, California 90502

University of Colorado Hospital
Denver, Colorado 80045

Yale New Haven Hospital
New Haven, Connecticut 06520

Washington Hospital Center
Washington, District of Columbia 20010

UF Health Shands Hospital
Gainesville, Florida 32610

University of Iowa Hospital and Clinics
Iowa City, Iowa 52242

University of Kentucky
Lexington, Kentucky 40536

LSU Health Science Center
New Orleans, Louisiana 70012

University of Maryland, Baltimore
Baltimore, Maryland 21201

Massachusetts General Hospital
Boston, Massachusetts 02114

Brigham and Women's Hospital
Boston, Massachusetts 02115

University of Michigan
Ann Arbor, Michigan 48109

Henry Ford Health System
Detroit, Michigan 48202

Fairview Southdale Hospital
Edina, Minnesota 55435

Hennepin County Medical Center
Minneapolis, Minnesota 55415

University of Minnesota Medical Center-Fairview
Minneapolis, Minnesota 55455

University of Missouri
Columbia, Missouri 65211

Capital Health System, Inc.
Trenton, New Jersey 98638

Erie County Medical Center-Affliate of SUNYat Buffalo
Buffalo, New York 14215

Carolinas Medical Center
Charlotte, North Carolina 28208

East Carolina University
Greenville, North Carolina 27834

University of Cincinnati Medical Center (UCMC)
Cincinnati, Ohio 45219

The Ohio State University
Columbus, Ohio 43210

Oregon Health and Science University
Portland, Oregon 97239

St. Luke's University Health Network
Bethlehem, Pennsylvania 18015

The Pennsylvania State University and The Milton S. Hershey Medical Center
Hershey, Pennsylvania 17033

The Trauma Center at PENN
Philadelphia, Pennsylvania 19104

Thomas Jefferson University
Philadelphia, Pennsylvania 19107

John Peter Smith Health Network
Fort Worth, Texas 76104

University of Texas Health Science Center at San Antonio
San Antonio, Texas 78229

Harborview Medical Center
Seattle, Washington 98104

University of Washington Medical Center
Seattle, Washington 98195

More Details

NCT ID
NCT03403751
Status
Recruiting
Sponsor
Atox Bio Ltd

Study Contact

David Wilfret, MD
919 439-3400
davidw@atoxbio.com

Detailed Description

Phase 2 randomized, placebo controlled study assessing the efficacy (complete recovery from AKI) and safety of Reltecimod in patients with suspected or confirmed abdominal sepsis (planned or completed surgical (laparotomy or laparoscopy) or interventional radiologic procedures for control of underlying abdominal infection within 24 hours of evaluation by medical personnel), requiring intensive care unit (ICU) or step down unit admission and in whom the diagnosis of Stage 2/3 acute kidney injury (AKI; as defined by Kidney Disease Improving Global Outcomes (KDIGO) criteria) is established at initial presentation for medical evaluation or up to 48 hours from the suspected diagnosis of abdominal sepsis.

Notice

Study information shown on this site is derived from ClinicalTrials.gov (a public registry operated by the National Institutes of Health). The listing of studies provided is not certain to be all studies for which you might be eligible. Furthermore, study eligibility requirements can be difficult to understand and may change over time, so it is wise to speak with your medical care provider and individual research study teams when making decisions related to participation.